CD274 and cancer: In multiple studies of adult cancers, higher levels of PD-L1 and a more inflamed TME correlated with a stronger response to immune checkpoint inhibitor therapy with antibodies blocking either PD-1 on T cells or its primary ligand, PD-L1, expressed on tumor cells and other cells of the TME [12–16].